This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Safety and Efficacy of Nicardipine for the Control of Blood Pressure After SAH

This study has been completed.
Information provided by:
University of Illinois at Chicago Identifier:
First received: June 20, 2007
Last updated: June 21, 2007
Last verified: June 2007
The purpose of this research is to explore ways to improve and simplify control of blood pressure in patients with SAH or ICH. This research will be done by comparing tow different medications that are routinely used to help control blood pressure. None of the medications used in this study nor any procedures performed are experimental.

Condition Intervention
Subarachnoid Hemorrhage Intracerebral Hemorrhage Drug: Nicardipine and Nipride

Study Type: Observational
Study Design: Observational Model: Defined Population
Observational Model: Natural History
Time Perspective: Longitudinal
Time Perspective: Prospective

Resource links provided by NLM:

Further study details as provided by University of Illinois at Chicago:

Enrollment: 163
Study Start Date: June 2004
Study Completion Date: February 2007

Ages Eligible for Study:   18 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • 18-70 years old (inclusive)
  • Admission to NSICU with a diagnosis of SAH or ICH

Exclusion Criteria:

  • Patients who are admitted >48 hours after SAH or ICH
  • Readmission or second SAH
  • Readmission or second ICH
  • Large (immediately life threatening) associated intraparenchymal or intraventricular hemorrhage
  • Women who are pregnant
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00490464

United States, Illinois
University of Illinois at Chicago, UIC
Chicago, Illinois, United States, 60612
Sponsors and Collaborators
University of Illinois at Chicago
Principal Investigator: Ben Z Roitberg, MD University of Illinois at Chicago, Department of Neurosurgery
  More Information Identifier: NCT00490464     History of Changes
Other Study ID Numbers: 2004-0233
Study First Received: June 20, 2007
Last Updated: June 21, 2007

Keywords provided by University of Illinois at Chicago:
Patients with SAH or ICH

Additional relevant MeSH terms:
Subarachnoid Hemorrhage
Cerebral Hemorrhage
Pathologic Processes
Intracranial Hemorrhages
Cerebrovascular Disorders
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Vascular Diseases
Cardiovascular Diseases
Antihypertensive Agents
Calcium Channel Blockers
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Vasodilator Agents processed this record on August 21, 2017